Outlook says FDA will sign off on its version of Avastin for wet AMD
After three FDA rejections dating back to 2023, Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the e...
After three FDA rejections dating back to 2023, Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the eye condition known as wet AMD. "The FDA concluded that substantial ...